Blog Archive
-
▼
2010
(63)
-
▼
April
(18)
- BioMarin Pharmaceutical : Positive Results for Pha...
- deCODE genetics "deCODEing Smoking: New Genetic Fa...
- Biodesix : VeriStrat® Outcomes Data in Lung Cancer...
- Johnson & Johnson Pharmaceutical Research and Deve...
- GeNO LLC : Investigational New Drug Application f...
- Spectrum Pharmaceuticals : Belinostat Data Present...
- Ariad : Preclinical Data on Its Investigational AL...
- Synta Pharmaceuticals : Results at AACR Supporting...
- Graceway Pharmaceuticals : Maxair Autohaler Remain...
- Patient Enrollment Complete in Tragara Pharmaceuti...
- Invida Group : Actelion Extends Partnership with I...
- Phadia : point of care in vitro specific IgE aller...
- Elekta : Next Generation SBRT for Lung Cancer with...
- NeoPharm : Orphan Drug Application Filing for IL13...
- Merrimack Pharmaceuticals : Enrollment in a Phase ...
- Clinical Data : Results of Phase I Studies of Sted...
- Pearl Therapeutics : Positive Results from Phase 1...
- Vectura to receive $9.5m payment and up to $25m lo...
-
▼
April
(18)
Apr 14, 2010
NeoPharm : Orphan Drug Application Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
Mar 10, 2010 - NeoPharm, Inc. (Other OTC: NEOL.PK), announced that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. IPF is the most deadly disease of the lungs in humans with very high morbidity. It is estimated that at least 55,000 patients are diagnosed with IPF each year in America and about 45,000 patients die each year with the disease. There is currently no proven effective treatment for the cure of this lethal disease...NeoPharm's Press Release -